SEQUENCE LISTING

<110> Genomix Co., Ltd.
Osaka University

<120> Method for treating damage of spinal cord with HMGB1 fragments

<130> G6-A1202P

<150> JP 2012-235786
<151> 2012-10-25

<160> 5

<170> PatentIn version 3.5

<210> 1
<211> 215
<212> PRT
<213> Homo sapiens

<400> 1

```
Met Gly Lys Gly Asp Pro Lys Lys Pro Arg Gly Lys Met Ser Ser Tyr
1               5                  10                  15

Ala Phe Phe Val Gln Thr Cys Arg Glu Glu His Lys Lys Lys His Pro
            20                  25                  30

Asp Ala Ser Val Asn Phe Ser Glu Phe Ser Lys Lys Cys Ser Glu Arg
        35                  40                  45

Trp Lys Thr Met Ser Ala Lys Glu Lys Gly Lys Phe Glu Asp Met Ala
    50                  55                  60

Lys Ala Asp Lys Ala Arg Tyr Glu Arg Glu Met Lys Thr Tyr Ile Pro
65                  70                  75                  80

Pro Lys Gly Glu Thr Lys Lys Lys Phe Lys Asp Pro Asn Ala Pro Lys
                85                  90                  95

Arg Pro Pro Ser Ala Phe Phe Leu Phe Cys Ser Glu Tyr Arg Pro Lys
            100                 105                 110

Ile Lys Gly Glu His Pro Gly Leu Ser Ile Gly Asp Val Ala Lys Lys
        115                 120                 125

Leu Gly Glu Met Trp Asn Asn Thr Ala Ala Asp Asp Lys Gln Pro Tyr
    130                 135                 140
```

```
Glu Lys Lys Ala Ala Lys Leu Lys Glu Lys Tyr Glu Lys Asp Ile Ala
145                 150                 155                 160

Ala Tyr Arg Ala Lys Gly Lys Pro Asp Ala Ala Lys Lys Gly Val Val
                165                 170                 175

Lys Ala Glu Lys Ser Lys Lys Lys Lys Glu Glu Glu Glu Asp Glu Glu
            180                 185                 190

Asp Glu Glu Asp Glu Glu Glu Glu Glu Asp Glu Glu Asp Glu Asp Glu
        195                 200                 205

Glu Glu Asp Asp Asp Asp Glu
    210                 215
```

<210> 2
<211> 648
<212> DNA
<213> Homo sapiens

<400> 2

```
atgggcaaag gagatcctaa gaagccgaga ggcaaaatgt catcatatgc atttttgtg
60

caaacttgtc gggaggagca taagaagaag cacccagatg cttcagtcaa cttctcagag
120

ttttctaaga agtgctcaga gaggtggaag accatgtctg ctaaagagaa aggaaaattt
180

gaagatatgg caaaagcgga caaggcccgt tatgaaagag aaatgaaaac ctatatccct
240

cccaaagggg agacaaaaaa gaagttcaag gatcccaatg cacccaagag gcctccttcg
300

gccttcttcc tcttctgctc tgagtatcgc ccaaaaatca aaggagaaca tcctggcctg
360

tccattggtg atgttgcgaa gaaactggga gagatgtgga ataacactgc tgcagatgac
420

aagcagcctt atgaaaagaa ggctgcgaag ctgaaggaaa aatacgaaaa ggatattgct
480

gcatatcgag ctaaaggaaa gcctgatgca gcaaaaaagg gagttgtcaa ggctgaaaaa
540

agcaagaaaa agaaggaaga ggaggaagat gaggaagatg aagaggatga ggaggaggag
600
```

gaagatgaag aagatgaaga tgaagaagaa gatgatgatg atgaataa
648

<210> 3
<211> 9
<212> PRT
<213> Artificial sequence

<220>
<223> An artificially synthesized peptide sequence

<400> 3

Ala Phe Phe Val Gln Thr Cys Arg Glu
1 5

<210> 4
<211> 34
<212> PRT
<213> Artificial sequence

<220>
<223> An artificially synthesized peptide sequence

<400> 4

Gly Lys Met Ser Ser Tyr Ala Phe Phe Val Gln Thr Cys Arg Glu Glu
1 5 10 15

His Lys Lys Lys His Pro Asp Ala Ser Val Asn Phe Ser Glu Phe Ser
20 25 30

Lys Lys

<210> 5
<211> 44
<212> PRT
<213> Artificial sequence

<220>
<223> An artificially synthesized peptide sequence

<400> 5

Met Gly Lys Gly Asp Pro Lys Lys Pro Arg Gly Lys Met Ser Ser Tyr
1 5 10 15

Ala Phe Phe Val Gln Thr Cys Arg Glu Glu His Lys Lys Lys His Pro
20 25 30

```
Asp Ala Ser Val Asn Phe Ser Glu Phe Ser Lys Lys
        35                  40
```